Novo Nordisk's veteran CEO Lars Rebien Sorensen has announced that he will step down earlier than planned.
Sorensen had said in April 2015 that he would remain in his role until he approached the end of his contract, expiring in 2019. The early retirement announcement comes as Novo says it has shaken up its management team to cope with “extraordinary change” and sharp headwinds for its core diabetes business.
Sorensen will be succeeded from January by Lars Fruergaard Jorgensen, currently executive vice president and head of corporate development.
Read the Reuters coverage